Rapid Micro Biosystems is a life sciences technology company providing automation solutions to facilitate the manufacturing and healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. Co.'s primary Growth Direct platform automates the antiquated, manual microbial quality control (MQC), testing workflows used in pharmaceutical manufacturing operations. Co.'s Growth Direct platform automates and digitizes the MQC and enables customers to perform this testing process. Co.'s platform comprises the Growth Direct system, proprietary consumables, laboratory information management system connection software, and customer support and validation services. The RPID average annual return since 2021 is shown above.
The Average Annual Return on the RPID average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether RPID average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the RPID average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|